NCT04233879

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

CompletedPHASE3INTERVENTIONAL

Trial Details

Start: 2020-02-28Est. Completion: 2022-11-17

Enrollment target: 599 participants

Locations

University of Alabama at Birmingham 1917 Research Clinic ( Site 5610), Birmingham, Alabama, United States
Pueblo Family Physicians ( Site 5606), Phoenix, Arizona, United States
Ruane Clinical Research Group, Inc. ( Site 5624), Los Angeles, California, United States
Midway Immunology and Research ( Site 5622), Ft. Pierce, Florida, United States
The Kinder Medical Group ( Site 5615), Miami, Florida, United States
Floridian Clinical Research, LLC ( Site 5625), Miami Lakes, Florida, United States
Orlando Immunology Center ( Site 5613), Orlando, Florida, United States
CAN Community Health ( Site 5627), Sarasota, Florida, United States
Triple O Research Institute, P.A. ( Site 5621), West Palm Beach, Florida, United States
Columbus Regional Research Institute ( Site 5616), Columbus, Georgia, United States
Infectious Disease Specialists Of Atlanta PC ( Site 5608), Decatur, Georgia, United States
Hennepin Healthcare-Hennepin Healthcare-ID ( Site 5633), Minneapolis, Minnesota, United States
Kansas City CARE Clinic ( Site 5607), Kansas City, Missouri, United States
University of Pennsylvania ( Site 5630), Philadelphia, Pennsylvania, United States

HIV-1-infection

The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with hum…

Buenos Aires, ArgentinaEst. completion Mar 2034

HIVHIV -1 Infection

The goal of this study is to understand the profile of individuals who demonstrate transmitted drug resistance to Dolute…

Manaus, BrazilCompleted Mar 8, 2024

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.